Xeljanz Articles
BioTrends views Xeljanz and Zytiga prescribing in USA
26 March 2013
Regulatory briefs on Bayer's Stivarga, Boehringer/Lilly's empagliflozin and Pfizer's Xeljanz
26 March 2013
FDA approves Pfizer's Xeljanz for rheumatoid arthritis
7 November 2012
Showing 1-6 of 6 articles
- 1
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Pfizer to split-off remaining 80% interest in Zoetis
